The interest of the IGF1R pathway is well understood for the development of targeted therapies in other solid tumors including the basal-like, triple negative breast cancer [45]; there is now ample evidence that this pathway is important also in luminal-type breast cancer and may play a role in the recurrence after endocrine therapy. The gene discussed is IGF1R; the disease is triple-negative breast carcinoma.